RxDoctor Payments DataLook up a doctor →

Stephanie Graff, MD

Hematology & Oncology · Kansas City, MONPI 1437187747

Payments from drug & device makers

$6,225,210in general payments, 2019–2025

Across 863 payments — averaging $7213.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2.8M
  • AstraZeneca$682K
  • Genentech, Inc.$652K
  • Eli Lilly$582K
  • Boehringer Ingelheim$499K
  • Daiichi Sankyo Inc.$449K
  • plus $554K from 18 others
$22,947in research payments, 2019–2025

Across 9 payments — averaging $2549.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$12K
  • Eli Lilly$11K
  • Novartis Pharma AG$69

What the payments were for

  • Consulting fees$66,84164%
  • Speaking & faculty fees$18,90018%
  • Grants$3500%
  • Travel & lodging$14,30314%
  • Food & beverage$4,1754%
  • Education$270%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,225,210 in reported general payments places this provider in the 95th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$24,753
Medicare patients
139
Services billed
233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib21$331,667
OrserduElacestrant Hcl11$262,759
Anastrozole291$4,427
Tamoxifen Citrate36$577
Letrozole20$473
Dexamethasone42$333
Prochlorperazine Maleate18$234
Ondansetron Hcl24$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance$40,294$331,66721 claims
Stemline Therapeutics Inc.Orserdu$2,220$262,75911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →